Share：
Share this content in WeChat
X
[Chinese][PDF]251
• Special Focu •
Radiology in assessment of neoadjuvant treatment efficacy in rectal cancer
SUN Yingshi  ZHANG Xiaoyan 

Cite this article as: SUN Y S, ZHANG X Y. Radiology in assessment of neoadjuvant treatment efficacy in rectal cancer[J]. Chin J Magn Reson Imaging, 2025, 16(1): 17-21. DOI:10.12015/issn.1674-8034.2025.01.003.


[Abstract] Neoadjuvant chemoradiotherapy (CRT) is the preferred first-line treatment for patients with locally advanced rectal cancer (LARC). Assessment of tumor response following CRT directly influences subsequent treatment decisions and long-term prognosis. Challenges in evaluating tumor response, particularly complete response, arise due to fibrosis, edema, and inflammation induced by CRT. Current standard methods for distinguishing complete response are unreliable and inadequate for clinical needs. The emergence of new imaging techniques and artificial intelligence offers hope for improving assessment of neoadjuvant treatment efficacy. This review focuses on current imaging evaluation methods and research progress, aiming to facilitate precise imaging-guided personalized treatment for rectal cancer.
[Keywords] rectal cancer；neoadjuvant chemoradiotherapy；treatment response evaluation；personalized treatment；artificial intelligence；magnetic resonance imaging；precision imaging

SUN Yingshi*   ZHANG Xiaoyan  

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Corresponding author: SUN Y S, E-mail: sys27@163.com

Conflicts of interest   None.

Received  2024-08-27
Accepted  2025-01-10
DOI: 10.12015/issn.1674-8034.2025.01.003
Cite this article as: SUN Y S, ZHANG X Y. Radiology in assessment of neoadjuvant treatment efficacy in rectal cancer[J]. Chin J Magn Reson Imaging, 2025, 16(1): 17-21. DOI:10.12015/issn.1674-8034.2025.01.003.

[1]
SAUER R, LIERSCH T, MERKEL S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a Median follow-up of 11 years[J]. J Clin Oncol, 2012, 30(16): 1926-1933. DOI: 10.1200/JCO.2011.40.1836.
[2]
SAUER R, BECKER H, HOHENBERGER W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740. DOI: 10.1056/NEJMoa040694.
[3]
TRAKARNSANGA A, GÖNEN M, SHIA J R, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment[J/OL]. J Natl Cancer Inst, 2014, 106(10): dju248 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/25249540/. DOI: 10.1093/jnci/dju248.
[4]
MACE A G, PAI R K, STOCCHI L, et al. American joint committee on cancer and college of American pathologists regression grade: a new prognostic factor in rectal cancer[J]. Dis Colon Rectum, 2015, 58(1): 32-44. DOI: 10.1097/DCR.0000000000000266.
[5]
HUH J W, KIM H C, KIM S H, et al. Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy[J]. Surgery, 2019, 165(3): 579-585. DOI: 10.1016/j.surg.2018.08.026.
[6]
PUCCIARELLI S, DE PAOLI A, GUERRIERI M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase Ⅱ clinical trial[J]. Dis Colon Rectum, 2013, 56(12): 1349-1356. DOI: 10.1097/DCR.0b013e3182a2303e.
[7]
PEREZ R O, HABR-GAMA A, LYNN P B, et al. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution[J]. Dis Colon Rectum, 2013, 56(1): 6-13. DOI: 10.1097/DCR.0b013e318273f56f.
[8]
RENEHAN A G, MALCOMSON L, EMSLEY R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis[J]. Lancet Oncol, 2016, 17(2): 174-183. DOI: 10.1016/S1470-2045(15)00467-2.
[9]
BARINA A, DE PAOLI A, DELRIO P, et al. Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study[J]. Tech Coloproctol, 2017, 21(8): 633-640. DOI: 10.1007/s10151-017-1665-1.
[10]
HABR-GAMA A, PEREZ R O, NADALIN W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results[J]. Ann Surg, 2004, 240(4): 711-718. DOI: 10.1097/01.sla.0000141194.27992.32.
[11]
DENG Y H, CHI P, LAN P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial[J]. J Clin Oncol, 2016, 34(27): 3300-3307. DOI: 10.1200/JCO.2016.66.6198.
[12]
PEREZ K, SAFRAN H, SIKOV W, et al. Complete neoadjuvant treatment for rectal cancer: the brown university oncology group CONTRE study[J]. Am J Clin Oncol, 2017, 40(3): 283-287. DOI: 10.1097/COC.0000000000000149.
[13]
DOSSA F, CHESNEY T R, ACUNA S A, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(7): 501-513. DOI: 10.1016/S2468-1253(17)30074-2.
[14]
MAOR Y, NADLER M, BARSHACK I, et al. Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiation[J]. J Gastroenterol Hepatol, 2006, 21(2): 454-458. DOI: 10.1111/j.1440-1746.2005.03927.x.
[15]
MEZZI G, ARCIDIACONO P G, CARRARA S, et al. Endoscopic ultrasound and magnetic resonance imaging for re-staging rectal cancer after radiotherapy[J]. World J Gastroenterol, 2009, 15(44): 5563-5567. DOI: 10.3748/wjg.15.5563.
[16]
MARTELLUCCI J, SCHEITERLE M, LORENZI B, et al. Accuracy of transrectal ultrasound after preoperative radiochemotherapy compared to computed tomography and magnetic resonance in locally advanced rectal cancer[J]. Int J Colorectal Dis, 2012, 27(7): 967-973. DOI: 10.1007/s00384-012-1419-5.
[17]
Department of Medical Administration of National Health Comimission, Chinese Society of Oncology. Chinese protocol of diagnosis and treatment of colorectal cancer of the National Health Commission (2023 edition)[J]. Chin J Gastrointest Surg, 2023, 26(6): 505-528. DOI: 10.3760/cma.j.cn441530-20230525-00182.
[18]
BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(7): 874-901. DOI: 10.6004/jnccn.2018.0061.
[19]
BEETS-TAN R G H, LAMBREGTS D M J, MAAS M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28(4): 1465-1475. DOI: 10.1007/s00330-017-5026-2.
[20]
AWIWI M O, KAUR H, ERNST R, et al. Restaging MRI of rectal adenocarcinoma after neoadjuvant chemoradiotherapy: imaging findings and potential pitfalls[J/OL]. Radiographics, 2023, 43(4): e220135 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/36927125/. DOI: 10.1148/rg.220135.
[21]
NOUGARET S, ROUANET P, MOLINARI N, et al. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy[J]. Radiology, 2012, 263(2): 409-418. DOI: 10.1148/radiol.12111263.
[22]
NOUGARET S, FUJII S, ADDLEY H C, et al. Neoadjuvant chemotherapy evaluation by MRI volumetry in rectal cancer followed by chemoradiation and total mesorectal excision: Initial experience[J]. J Magn Reson Imaging, 2013, 38(3): 726-732. DOI: 10.1002/jmri.23905.
[23]
HAN Y B, OH S N, CHOI M H, et al. Clinical impact of tumor volume reduction in rectal cancer following preoperative chemoradiation[J]. Diagn Interv Imaging, 2016, 97(9): 843-850. DOI: 10.1016/j.diii.2016.05.004.
[24]
SANTIAGO I, BARATA M, FIGUEIREDO N, et al. The split scar sign as an indicator of sustained complete response after neoadjuvant therapy in rectal cancer[J]. Eur Radiol, 2020, 30(1): 224-238. DOI: 10.1007/s00330-019-06348-9.
[25]
PATEL U B, TAYLOR F, BLOMQVIST L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience[J]. J Clin Oncol, 2011, 29(28): 3753-3760. DOI: 10.1200/JCO.2011.34.9068.
[26]
HE H, CHEN S Y, HU F B. Application status of tumor regression grading method after neoadjuvant chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer[J]. Chin J Magn Reson Imag, 2024, 15(7): 204-209. DOI: 10.12015/issn.1674-8034.2024.07.034.
[27]
JAYAPRAKASAM V S, ALVAREZ J, OMER D M, et al. Watch-and-wait approach to rectal cancer: the role of imaging[J/OL]. Radiology, 2023, 307(1): e221529 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/36880951/. DOI: 10.1148/radiol.221529.
[28]
DE JONG E A, BERGE J C E M TEN, DWARKASING R S, et al. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis[J]. Surgery, 2016, 159(3): 688-699. DOI: 10.1016/j.surg.2015.10.019.
[29]
MEMON S, LYNCH A C, BRESSEL M, et al. Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy[J]. Colorectal Dis, 2015, 17(9): 748-761. DOI: 10.1111/codi.12976.
[30]
ZHAO R S, WANG H, ZHOU Z Y, et al. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis[J]. Dis Colon Rectum, 2014, 57(3): 388-395. DOI: 10.1097/DCR.0000000000000022.
[31]
PANG X L, XIE P Y, YU L, et al. A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer[J]. Br J Cancer, 2022, 127(2): 268-277. DOI: 10.1038/s41416-022-01801-x.
[32]
GUAN Z, SUN R J, CAO W T, et al. Magnetic resonance imaging tumor response score (mrTRS) predicts therapeutic effect and prognosis of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a prospective, multi-center study[J]. Radiother Oncol, 2020, 151: 288-295. DOI: 10.1016/j.radonc.2020.08.028.
[33]
LU Q Y, GUAN Z, ZHANG X Y, et al. Contrast-enhanced MRI for T restaging of locally advanced rectal cancer following neoadjuvant chemotherapy and radiation therapy[J]. Radiology, 2022, 305(2): 364-372. DOI: 10.1148/radiol.212905.
[34]
YANG A, ZHOU P. Progress of quantitative prediction of the pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer with functional MRI[J]. Chin J Magn Reson Imag, 2024, 15(7): 210-215. DOI: 10.12015/issn.1674-8034.2024.07.035.
[35]
CHEN W C, MAO L T, LI L, et al. Predicting treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer using amide proton transfer MRI combined with diffusion-weighted imaging[J/OL]. Front Oncol, 2021, 11: 698427 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/34277445/. DOI: 10.3389/fonc.2021.698427.
[36]
NISHIE A, ASAYAMA Y, ISHIGAMI K, et al. Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. J Gastroenterol Hepatol, 2019, 34(1): 140-146. DOI: 10.1111/jgh.14315.
[37]
KIM M J, LEE S J, LEE J H, et al. Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy[J]. Magn Reson Imaging, 2012, 30(6): 848-853. DOI: 10.1016/j.mri.2012.02.013.
[38]
AIBA T, UEHARA K, NIHASHI T, et al. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. Ann Surg Oncol, 2014, 21(6): 1801-1808. DOI: 10.1245/s10434-014-3538-4.
[39]
JOYE I, DEROOSE C M, VANDECAVEYE V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review[J]. Radiother Oncol, 2014, 113(2): 158-165. DOI: 10.1016/j.radonc.2014.11.026.
[40]
CRIMÌ F, SPOLVERATO G, LACOGNATA C, et al. 18F-FDG PET/MRI for rectal cancer TNM restaging after preoperative chemoradiotherapy: initial experience[J]. Dis Colon Rectum, 2020, 63(3): 310-318. DOI: 10.1097/DCR.0000000000001568.
[41]
FRAUM T J, LUDWIG D R, HOPE T A, et al. PET/MRI for gastrointestinal imaging: current clinical status and future prospects[J]. Gastroenterol Clin North Am, 2018, 47(3): 691-714. DOI: 10.1016/j.gtc.2018.04.011.
[42]
MIRSHAHVALAD S A, HINZPETER R, KOHAN A, et al. Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2022, 49(12): 4205-4217. DOI: 10.1007/s00259-022-05871-0.
[43]
CRIMÌ F, VALEGGIA S, BAFFONI L, et al. [18F] FDG PET/MRI in rectal cancer[J]. Ann Nucl Med, 2021, 35(3): 281-290. DOI: 10.1007/s12149-021-01580-0.
[44]
NIE K, SHI L M, CHEN Q, et al. Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI[J]. Clin Cancer Res, 2016, 22(21): 5256-5264. DOI: 10.1158/1078-0432.CCR-15-2997.
[45]
LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[46]
LIU Z Y, ZHANG X Y, SHI Y J, et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Clin Cancer Res, 2017, 23(23): 7253-7262. DOI: 10.1158/1078-0432.CCR-17-1038.
[47]
LI Z Y, WANG X D, LI M, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer[J]. World J Gastroenterol, 2020, 26(19): 2388-2402. DOI: 10.3748/wjg.v26.i19.2388.
[48]
SHIN J, SEO N, BAEK S E, et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy[J]. Radiology, 2022, 303(2): 351-358. DOI: 10.1148/radiol.211986.
[49]
CUI Y F, YANG X T, SHI Z Q, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Eur Radiol, 2019, 29(3): 1211-1220. DOI: 10.1007/s00330-018-5683-9.
[50]
GIANNINI V, MAZZETTI S, BERTOTTO I, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features[J]. Eur J Nucl Med Mol Imaging, 2019, 46(4): 878-888. DOI: 10.1007/s00259-018-4250-6.
[51]
CAPELLI G, CAMPI C, BAO Q R, et al. 18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy[J]. Nucl Med Commun, 2022, 43(7): 815-822. DOI: 10.1097/MNM.0000000000001570.
[52]
NARDONE V, REGINELLI A, GRASSI R, et al. Ability of delta radiomics to predict a complete pathological response in patients with loco-regional rectal cancer addressed to neoadjuvant chemo-radiation and surgery[J/OL]. Cancers, 2022, 14(12): 3004 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/35740669/. DOI: 10.3390/cancers14123004.
[53]
WANG L K, WU X L, TIAN R X, et al. MRI-based pre-Radiomics and delta-Radiomics models accurately predict the post-treatment response of rectal adenocarcinoma to neoadjuvant chemoradiotherapy[J/OL]. Front Oncol, 2023, 13: 1133008 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/36925913/. DOI: 10.3389/fonc.2023.1133008.
[54]
JAYAPRAKASAM V S, PARODER V, GIBBS P, et al. MRI radiomics features of mesorectal fat can predict response to neoadjuvant chemoradiation therapy and tumor recurrence in patients with locally advanced rectal cancer[J]. Eur Radiol, 2022, 32(2): 971-980. DOI: 10.1007/s00330-021-08144-w.
[55]
CHILOIRO G, CUSUMANO D, ROMANO A, et al. Delta radiomic analysis of mesorectum to predict treatment response and prognosis in locally advanced rectal cancer[J/OL]. Cancers, 2023, 15(12): 3082 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/37370692/. DOI: 10.3390/cancers15123082.
[56]
ZHANG X Y, WANG L, ZHU H T, et al. Predicting rectal cancer response to neoadjuvant chemoradiotherapy using deep learning of diffusion kurtosis MRI[J]. Radiology, 2020, 296(1): 56-64. DOI: 10.1148/radiol.2020190936.
[57]
JANG B S, LIM Y J, SONG C, et al. Image-based deep learning model for predicting pathological response in rectal cancer using post-chemoradiotherapy magnetic resonance imaging[J]. Radiother Oncol, 2021, 161: 183-190. DOI: 10.1016/j.radonc.2021.06.019.
[58]
JIN C, YU H, KE J, et al. Predicting treatment response from longitudinal images using multi-task deep learning[J/OL]. Nat Commun, 2021, 12(1): 1851 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/33767170/. DOI: 10.1038/s41467-021-22188-y.
[59]
KE J, JIN C, TANG J H, et al. A longitudinal MRI-based artificial intelligence system to predict pathological complete response after neoadjuvant therapy in rectal cancer: A multicenter validation study[J/OL]. Dis Colon Rectum, 2023, 66(12): e1195-e1206 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/37682775/. DOI: 10.1097/DCR.0000000000002931.
[60]
XIA S J, LI Q Y, ZHU H T, et al. Fully semantic segmentation for rectal cancer based on post-nCRT MRl modality and deep learning framework[J/OL]. BMC Cancer, 2024, 24(1): 315 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/38454349/. DOI: 10.1186/s12885-024-11997-1.
[61]
FENG L L, LIU Z Y, LI C F, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study[J/OL]. Lancet Digit Health, 2022, 4(1): e8-e17 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/34952679/. DOI: 10.1016/S2589-7500(21)00215-6.
[62]
WAN L J, SUN Z, PENG W J, et al. Selecting candidates for organ-preserving strategies after neoadjuvant chemoradiotherapy for rectal cancer: development and validation of a model integrating MRI radiomics and pathomics[J]. J Magn Reson Imaging, 2022, 56(4): 1130-1142. DOI: 10.1002/jmri.28108.
[63]
JIA L L, ZHENG Q Y, TIAN J H, et al. Artificial intelligence with magnetic resonance imaging for prediction of pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis[J/OL]. Front Oncol, 2022, 12: 1026216 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/36313696/. DOI: 10.3389/fonc.2022.1026216.
[64]
SHEN H, JIN Z, CHEN Q Y, et al. Image-based artificial intelligence for the prediction of pathological complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review and meta-analysis[J]. Radiol Med, 2024, 129(4): 598-614. DOI: 10.1007/s11547-024-01796-w.
[65]
HAIBE-KAINS B, ADAM G A, HOSNY A, et al. Transparency and reproducibility in artificial intelligence[J/OL]. Nature, 2020, 586(7829): E14-E16 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/33057217/. DOI: 10.1038/s41586-020-2766-y.
[66]
RIVERA S C, LIU X X, CHAN A W, et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension[J/OL]. BMJ, 2020, 370: m3210 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/32907797/. DOI: 10.1136/bmj.m3210.
[67]
LIU X X, RIVERA S C, MOHER D, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension[J/OL]. BMJ, 2020, 370: m3164 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/33328048/. DOI: 10.1136/bmj.m3164.
[68]
LI Q Y, YANG D, GUAN Z, et al. Extranodal extension at pretreatment MRI and the prognostic value for patients with rectal cancer[J/OL]. Radiology, 2024, 310(3): e232605 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/38530176/. DOI: 10.1148/radiol.232605.
[69]
KIM T H, FIRAT C, THOMPSON H M, et al. Extramural venous invasion and tumor deposit at diffusion-weighted MRI in patients after neoadjuvant treatment for rectal cancer[J/OL]. Radiology, 2023, 308(2): e230079 [2024-08-26]. https://pubmed.ncbi.nlm.nih.gov/37581503/. DOI: 10.1148/radiol.230079.

PREV Chinese expert consensus on imaging assessment of limb shock injuries
NEXT Deep learning based on multiparametric magnetic resonance imaging features to predict BRAF gene mutation status in rectal cancer patients
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn